Page last updated on July 16, 2024
PDS Biotechnology Corp reported their cybersecurity risk management and governance process in a yearly 10-K filed on 2024-03-28 17:16:48 EDT.
Filings
10-K filed on 2024-03-28
PDS Biotechnology Corp filed a 10-K at 2024-03-28 17:16:48 EDT
Accession Number: 0001140361-24-016265
Note: filing items unformatted. Drop us a note with the above URL to help us prioritize formatting it!
Item 1C. Cybersecurity.
ITEM 1C. Cybersecurity Risk Management and Strategy We assess material risks from cybersecurity threats on an ongoing basis, including any potential unauthorized access to or occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein. As we grow, we plan to develop a more robust and detailed strategy for cybersecurity in alignment with nationally accepted standards. Our cybersecurity program is overseen by our head of human resources, information technology (IT) and facilities, who manages our third-party providers of IT services. We have engaged contractors to provide cybersecurity standards, architecture and processes. As part of our service agreement with our contractors, we receive identification and reporting of risks to our management and board. Our information technology team maintains a security operations center intended to identify anomalous activity. Further, our policies require all employees to notify our compliance, legal or information technology functions in the event of a cybersecurity incident. As of the date of this Annual Report on Form 10-K, we are not aware of any cybersecurity threats, including as a result of any previous cybersecurity incidents, that have materially affected us, including our business strategy, results of operations or financial condition. Our business depends on the availability, reliability and security of our and our third-party contractors’ information systems, networks and data. As discussed under “Risk Factors” in Part I, Item 1A of this Annual Report, cybersecurity threats pose multiple risks to us, including potentially to our results of operations and financial condition. For additional information concerning risks related to cybersecurity, see Item 1.A. Risk Factors: “Our business and operations would suffer, and could be negatively affected, in the event of system failures or cyberattacks .” Governance Our management oversees and reviews any reports of cybersecurity risks or breaches provided by our third-party providers of IT services. Additionally, management assesses potential improvements to our cybersecurity policies and procedures based on recommendations from third-party experts, including our providers of IT services, in a matter that’s suitable for a company our size and nature. One of our Board’s key functions is informed oversight of our risk management process, including risks from cybersecurity threats. The Board does not have a standing risk management committee, but rather administers this oversight function directly through the Board as a whole, as well as through various Board standing committees that address risks inherent in their respective areas of oversight. Our Audit Committee has the responsibility to review and discuss with management and KPMG LLP, the Company’s independent auditors, as appropriate, our guidelines and policies with respect to risk assessment and risk management, including our major financial risk exposures and the steps taken by management to monitor and control these exposures, including as it concerns risks from cybersecurity threats. In general, we seek to address cybersecurity risks through a cross-functional approach that is focused on preserving the confidentiality, integrity, and availability of the information that we collect and store by identifying, preventing, and mitigating cybersecurity threats and effectively responding to cybersecurity incidents when they occur.
Company Information
Name | PDS Biotechnology Corp |
CIK | 0001472091 |
SIC Description | Pharmaceutical Preparations |
Ticker | PDSB - Nasdaq |
Website | |
Category | Non-accelerated filer Smaller reporting company |
Fiscal Year End | December 30 |